The Global Drug sales of Tecentriq stood at USD 4,066.81 Millions in 2022
The indicator recorded a historical growth (CAGR) of29% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to grow at a CAGR of...
Atezolizumab (Tecentriq) is an antineoplastic agent. It is formulated as solution concentrate for intravenous route of administration.
Mechanism of Action
Atezolizumab (RG7446) is an anti-PD-L1 (programmed cell death–1 ligand 1) monoclonal antibody. Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a B7 family member. PD-L1 does not interact with either CD28 or CTLA-4. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Negative regulatory mechanisms within the solid tumor micro-environment inhibit anti-tumor T-cell function, leading to evasion from immune attack. One inhibitory mechanism is up-regulation of programmed death-ligand 1 (PD-L1) expressed on tumor or stromal cells which binds to programmed death-1 (PD-1) on activated T cells. Upon ligating its receptor, PD-L1 has been decreased TCR-mediated proliferation and cytokine production. Thus, PD-L1 might play an important role in tumor suppression.
Tecentriq Overview
Tecentriq is marketed for the treatment of several indications in oncology therapy area.
Tecentriq is indicated for the treatment of urothelial bladder cancer (second line), for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities, locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy, and in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations, and in combination with Avastin (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC), and in combination with chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area), as determined by an FDA-approved test and in combination with abraxane, paclitaxel and carboplatin is indicated for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations, and in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Tecentriq was first approved in 2016 and is sold globally including the US, the UK, France, Germany, and Japan by F. Hoffmann-La Roche Ltd. Tecentriq drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward